Sab Biotherapeutics, Inc. · NASDAQ:SABS
Balyasny Asset Management L.P. reported a 9.99% stake in Sab Biotherapeutics, Inc. (Schedule 13G)
Event Mar 31, 2026 · Filed May 15, 2026
Balyasny Asset Management L.P. reported a 9.99% stake in Sab Biotherapeutics, Inc., 5,089,939 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 5,089,939
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Balyasny Asset Management L.P. | 9.99% | 5,089,939 |
| BAM GP LLC | 9.99% | 5,089,939 |
| Balyasny Asset Management Holdings LP | 9.99% | 5,089,939 |
| Dames GP LLC | 9.99% | 5,089,939 |
| Dmitry Balyasny | 9.99% | 5,089,939 |
Source
Related
- Sab Biotherapeutics, Inc.
- Balyasny Asset Management L.P.
- Sab Biotherapeutics, Inc. shareholders
- Schedule 13G/A · Balyasny Asset Management L.P. · Aug 14, 2026
- Form 4 · Kropotova Alexandra · Sep 18, 2026
- Schedule 13G/A · Vivo Opportunity, LLC · Aug 14, 2026
- Schedule 13G/A · Woodline Partners LP · Aug 14, 2026
- Schedule 13G/A · Caligan Partners LP · Aug 14, 2026
- Schedule 13G/A · Commodore Capital LP · Aug 14, 2026